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Epidemiological studies based on the “hygiene hypothesis” declare that the level of 
childhood exposure to environmental microbial products is inversely related to the 
incidence of allergic diseases in later life. Multiple types of immune cell-mediated 
immune regulation networks support the hygiene hypothesis. Epithelial cells are the first 
line of response to microbial products in the environment and bridge the innate and 
adaptive immune systems; however, their role in the hygiene hypothesis is unknown. To 
demonstrate the hygiene hypothesis in airway epithelial cells, we examined the effect of 
lipopolysaccharide (LPS; toll-like receptor 4 ligand) on the expression of the proallergic 
cytokines thymic stromal lymphopoietin (TSLP) and interleukin 33 (IL33) in H292 cells 
(pulmonary mucoepidermoid carcinoma cells). Stimulation with the TLR ligand polyI:C 
and human parechovirus type 1 (HPeV1) but not LPS-induced TSLP and IL33 through 
interferon regulatory factor 3 (IRF3) and NF-κB activity, which was further validated by 
using inhibitors (dexamethasone and Bay 11-7082) and short hairpin RNA-mediated 
gene knockdown. Importantly, polyI:C and HPeV1-stimulated TSLP and IL33 induc-
tion was reduced by LPS treatment by attenuating TANK-binding kinase 1, IRF3, and 
NF-κB activation. Interestingly, the basal mRNA levels of TLR signaling proteins were 
downregulated with long-term LPS treatment of H292 cells, which suggests that such 
long-term exposure modulates the expression of innate immunity signaling molecules in 
airway epithelial cells to mitigate the allergic response. In contrast to the effects of LPS 
treatment, the alarmin high-mobility group protein B1 acts in synergy with polyI:C to 
promote TSLP and IL33 expression. Our data support part of the hygiene hypothesis in 
airway epithelia cells in vitro. In addition to therapeutic targeting of TSLP and IL33, local 
application of non-pathogenic LPS may be a rational strategy to prevent allergies.
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inTrODUcTiOn
The hygiene hypothesis declares that a lack of early childhood 
exposure to environmental microorganisms and pathogens 
increases susceptibility to allergic diseases by suppressing the 
establishment of immune tolerance (1). Epidemiological data 
and experimental evidence showed that exposure to environ-
mental pathogen-associated molecular patterns (PAMPs), such 
as lipopolysaccharide (LPS), are associated with decreasing 
the incidence of allergic diseases in later life (2–4). Similarly, 
muramic acid, a constituent of peptidoglycan of bacteria in the 
environment was found inversely associated with respiratory 
wheezing in rural school children (5). Those reports suggest that 
environmental microbes modulate allergic response.
Innate immunity is a rapid host defense response against 
invading pathogens, this response is essential to establish anti-
gen-specific adaptive immunity to further eradicate pathogens 
and instruct the immune memory (6). Human epithelial cells 
form the largest primary physical barrier against environmental 
microbes and provide protection to the host via TLR-mediated 
responses of innate immunity (7–9). TLR signaling in skin and 
airway epithelial cells promotes the expression of proallergic 
cytokines, such as thymic stromal lymphopoietin (TSLP), 
granulocyte-macrophage colony-stimulating factor, interleu-
kin-25 (IL25), and IL33, which are crucial for the initiation 
of the Th2 allergic immune cascade (7, 10–14). Epithelial cells 
command the innate and adaptive immune responses in atopic 
diseases (15). The implication of epithelial cells expressing the 
proallergic cytokines TSLP and IL33 in hygiene hypothesis is 
unknown.
Childhood exposure to environmental microorganism, such 
as viral infection can exacerbate asthma severity. Viral infection 
with rhinovirus, human metapneumovirus and respiratory 
syncytial virus can induce TSLP expression in airway epithelial 
cells (9, 16, 17). In particular, rhinovirus infection has been found 
associated with TSLP levels in the airways of young children 
(18). Rhinovirus infection can induce IL33 secretion in human 
bronchial epithelial cells to promote Th2 inflammation and exac-
erbate asthma severity in patients (19). This finding agreed with 
the observation of higher IL33 levels in the sera of patients with 
allergic rhinitis than normal controls (20). In addition, human 
parechovirus (HPeV), a small, round-structured, non-enveloped 
virus with a single-stranded and positive-sense RNA genome, 
belongs to the Picornaviridae (21). Nosocomial infection or 
outbreaks in neonate hospital departments seem to play a large 
role in HPeV infection (22, 23). Similar to rhinovirus, HPeV also 
causes respiratory disease in children, with high prevalence (24). 
It would be interested to understand whether HPeV1 acts like 
rhinovirus on prompting allergy.
Virus infection also can increase and activate TLR3 signal 
pathway (25). Among the various TLR ligands, only polyI:C 
(double-stranded RNA, TLR3 ligand) can stimulate high levels of 
TSLP expression, which is enhanced by the addition of IL4, IL13, 
or tumor necrosis factor α (26). Other TLR ligands, such as LPS 
(TLR4 ligand), CpG (TLR9 ligand), Pam3CSK4 (TLR2 ligand), 
and flagellin (TLR5 ligand), failed to induce TSLP expression in 
epithelial cells (16, 26). Similarly, IL33 mRNA expression could be 
induced by IFN-γ, the TLR9 ligand ODN2006, or polyI:C but not 
LPS in human nasal epithelial cells with allergic rhinitis (20, 27).
The immunoregulatory effect of the LPS/TLR4 axis in immune 
cells, such as dendritic cells and myeloid-derived suppressor cells 
was revealed in an animal model of asthma, which suggested that 
the dose of LPS is critical for the T helper 1 (Th1)/Th2 cell bal-
ance. Increased doses of LPS and antigens induce Th1 responses 
and inhibit allergic inflammation; however, reduced doses of 
LPS induce Th2 responses and promote airway inflammation 
(28–31). In addition to LPS, the TLR2 ligand Pam3CSK4 blocks 
the development of asthma (32). Therefore, TLRs in immune cells 
play roles during allergic airway responses.
The LPS failure to induce expression of TSLP and IL-33 
prompted us to explore the mechanism by which LPS down-
regulates allergic cytokine production in response to polyI:C 
stimulation in airway epithelial cells. We established an in vitro 
model of the hygiene hypothesis in human airway epithelial 
mucoepidermoid pulmonary carcinoma cells (H292 cells) and 
used polyI:C treatment to mimic double-stranded viral RNA 
during replication to trigger inflammation (15, 26). We used 
our previously isolated and characterized clinical virus isolate, 
HPeV1 (33), to address whether LPS regulates virus-mediated 
allergic inflammation. The effects of LPS on polyI:C- and 
HPeV1-stimulated TSLP and IL33 mRNA expression were 
measured. Mechanistically, we also examined how LPS sign-
aling subverts the polyI:C and HPeV1 signal axis in airway 
epithelial cells.
The non-histone nuclear protein high-mobility group protein 
B1 (HMGB1) is a damage-associated molecular pattern (DAMP) 
or called alarmin, which is released outside of the cells while cell 
activation, injury, or death (34). The HMGB1-mediated airway 
inflammation disease was characterized in the clinical and experi-
mental asthma (35). In addition, HMGB1 from airway epithelial 
cells with respiratory syncytial virus infection primes epithelial 
cells and monocytes to inflammation stimuli in the airway (36). 
Multiple receptors were identified to be interacted with HMGB1, 
such as the receptor of advanced glycation end products (RAGE) 
or integrins, etc. (34). In addition, HMGB1 may act as an endog-
enous TLR2/4 ligand to trigger inflammatory responses (34, 37, 
38). Thus, in this study, we also investigated whether HMGB1 
regulates the TSLP and IL33 expression in polyI:C-stimulated 
airway epithelial cells.
MaTerials anD MeThODs
cells
The human mucoepidermoid pulmonary carcinoma cell line 
NCI-H292 (BCRC, 60732) was cultured in RPMI1640 medium 
(Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal 
bovine serum (FBS; Invitrogen) and 1% penicillin/streptomycin 
(Invitrogen) at 37°C in a 5% CO2 atmosphere. The human bron-
chial epithelial cell line NL-20 (ATCC-CRL-2503) was cultured in 
Ham’s F12 medium (Invitrogen, Carlsbad, CA, USA) with 10 ng/
ml epidermal growth factor, 0.001  mg/ml transferrin, 500  ng/
ml hydrocortisone, and 4% FBS and 1% penicillin/streptomycin 
(Invitrogen) at 37°C in a 5% CO2 atmosphere. A549 human lung 
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epithelial carcinoma cells (ATCC: CCL-185), WS1 human fetal 
skin normal fibroblasts (BCRC: 60300), and HEK-293T cells 
(ATCC: CRL-3216) were cultured in DMEM supplemented with 
10% fetal bovine serum and 1% penicillin/streptomycin at 37°C 
in a 5% CO2 atmosphere. The human primary nasal epithelium 
from three donors was isolated and cultured according to the 
previous report (39). The study was approved by the Institutional 
Review Board of Kaohsiung Veterans General Hospital (Protocol 
number: VGHKS98-VT8-06) and conformed to the current ethi-
cal principles of the Declaration of Helsinki. Written informed 
consents were obtained from all donors.
reagents
The double-stranded RNA, polyI:C, from Sigma-Aldrich (#P1530) 
and InvivoGen (#tlrl-picw) were used. Our testing results showed 
that the two polyI:C products of polyI:C have the similar activity 
of TSLP induction in H292 cells (Figure S1A in Supplementary 
Material). So, in this study, the polyI:C from Sigma-Aldrich was 
used.
Lipopolysaccharide from Escherichia coli 0111:B4 (#L2630), 
Escherichia coli 055:B5 (#L2880), Escherichia coli 026:B6 (#L-
8274), Escherichia coli 0127:B8 (#L4516), Klebsiella pneumoniae 
(L4268), Salmonella enterica serotype enteritidis (#L7770), 
Salmonella enterica serotype minnesota (#L6261), Pseudomonas 
aeruginosa 10 (#L9143), dexamethasone (#D4902), and Bay 
11-7082 (#B5556) were all from Sigma-Aldrich (St. Louis, MO, 
USA) (40). We tested these eight different LPS in the TSLP and 
IL33 induction. Except the LPS from Escherichia coli 0127:B8, 
other seven types of LPS were not able to promote TSLP and 
IL33 expression; moreover, the polyI:C-induced TSLP and IL33 
expression were attenuated by all of the tested LPS (Figures S1B,C 
in Supplementary Material). Based on the results of statistical 
analysis, the LPS from Escherichia coli 0111:B4 was chosen in 
this study.
Recombinant human IL4 and HMGB1 were from Peprotech 
and R&D system, respectively (Rocky Hill, NJ, USA and 
Minneapolis, MN, USA). The expression vectors of IRF3, IRFs 
5D, and IRF3 5A were described in our previous report (41). 
TurboFect transfection reagent (Thermo Scientific) was used for 
transient transfection following the manufacturer’s protocol.
hPeV1 and Virus Titration
The strains of HPeV1 KVP6 (accession no. KC769584) were 
isolated by the Virology Group, Department of Microbiology, 
Kaohsiung Veterans General Hospital and propagated in Vero 
cells (ATCC: CCL-81) (33). To determine the virus titers, culture 
medium from HPeV1-infected cells were harvested for plaque-
forming assays. Various virus dilutions were added to 6-well 
plates with 80% confluent Vero cells and incubated at 37°C for 2 h. 
After adsorption, cells were gently washed and overlaid with 1% 
agarose containing MEM supplemented with FBS. After 7 days’ 
incubation at 37°C, cells were fixed with 10% formaldehyde, then 
stained with 1% crystal violet for further plaque counting.
Treatment
The treatment condition of polyI:C and IL4 or HPeV1 infection 
was evaluated with the TSLP induction in various cell types. 
H292 cells (1 ×  106) in 6-well plates were either transfected 
by 2.5 μg polyI:C with TurboFect or directly incubated with 
30 μg/ml polyI:C-contained medium. The TSLP mRNA level 
was highly induced at 3 h post-stimulation and then declined 
at 6  h in both treatments; particularly, polyI:C transfection 
showed greater induction level of TSLP than just adding 
polyI:C (Figure S2A in Supplementary Material). Therefore, 
the method of polyI:C (2.5  μg) transfection was set for the 
allergic cytokine induction in this study. This treatment 
condition was confirmed in another cell types in A549 cells, 
which TSLP mRNA was promoted with polyI:C stimulation at 
3 h, 6 h, and 12 h, and then declined at 24 h (Figure S2B in 
Supplementary Material). Similar results were observed in the 
NL20 cells (Figure S3A in Supplementary Material). The TSLP 
protein level was detected by immunoblotting, which showed 
the increased protein level of TSLP in H292 cells at 3–6 h and 
in A549 cells at 2–3 h after polyI:C transfection; then, the TSLP 
protein level was decreased in later time points (Figure S2C in 
Supplementary Material).
The TSLP induction by different concentration of recombi-
nant IL4 was measured in H292 cells. Only the concentration 
of 20 ng/ml, but not 1 and 10 ng/ml, of IL4 was able to induce 
TSLP, the level was peaked at 3 h post-stimulation (Figure S2D in 
Supplementary Material). The TSLP induction by 20 ng/ml of IL4 
had also detected in WS1 human fetal skin normal fibroblasts with 
a time course-dependent manner (Figure S2E in Supplementary 
Material).
HPeV1 infection-mediated innate immune activation in A549 
cells was revealed in our previous report (33). Here, we also found 
TSLP induction in A549 cells infected with HPeV1 at multiplicity 
of infection (MOI) = 5. Two induction peaks were observed at 
2 and 36  h post infection (hpi) (Figure S2F in Supplementary 
Material).
Before LPS treatment, the cell culture medium was replaced 
with serum-free RPMI medium for 1 h, and then various con-
centrations of LPS were added to the cells and incubated for 2 h 
for short-term LPS treatment. LPS-treated cells were stimulated 
with polyI:C or infected with HPeV1 for the indicated times. In 
certain case, the cells were stimulated by recombinant IL4 (20 ng/
ml) or HMGB1 (1 μg/ml). For long-term LPS treatment, H292 
cells were incubated with LPS (30 μg/ml) for 8 or 16 days, or LPS 
(0.3 μg/ml) for 60 days, and the LPS-containing growth medium 
was refreshed every 2 days. Before polyI:C stimulation, long-term 
LPS-treated H292 cells were incubated with serum-free medium 
for 1 h followed by LPS treatment for 2 h, then stimulated with 
polyI:C for 3 h. In the inhibitor treatment group, dexamethasone 
or Bay 11-7082 was added to cells, and cells were incubated for 
2 h before stimulation with polyI:C.
cell Proliferation assay
WST-1 assay (Roche, Basel, Switzerland) was used to moni-
tor cell proliferation (42, 43); H292 cells were trypsinized and 
resuspended in culture medium, then plated at 5 × 103 cells per 
well in 96-well plates and incubated overnight. After LPS treat-
ment followed by polyI:C transfection, cells were incubated with 
10 μl WST-1 reagent for 2 h. The cell viability was quantified by 
multi-well spectrophotometry (Anthos, Biochrom, Cambridge, 
4Lin et al. LPS Attenuates Allergic Cytokines Induction
Frontiers in Immunology | www.frontiersin.org October 2016 | Volume 7 | Article 440
UK). The absorbance at 450 nm was monitored, and the reference 
wavelength was set at 620 nm.
Quantitative real-time Pcr
Total RNA was extracted by using TRIzol reagent (Thermo Fisher 
Scientific) according to the manufacturer’s instructions. The 
cDNA was synthesized from 5 μg total RNA by using a Superscript 
III reverse transcriptase kit (Thermo Fisher Scientific) with 
oligo (dT) primers. Real-time PCR involved 10 ng total cDNA 
and SYBR green master mix (Applied Biosystems, Carlsbad, 
CA, USA) with the ABI StepOne Plus Real-Time PCR System 
(Applied Biosystems) (44). The primers for qPCR are in Table S1 
in Supplementary Material. The relative mRNA level was nor-
malized to that of glyceraldehyde-3-phosphate dehydrogenase 
(GADPH), as a loading control.
immunoblotting
Cells were lysed in 2% SDS buffer [2% SDS, 50  mM Tris–HCl 
(pH 7.5), 20  mM N-ethylmaleimide plus complete protease 
inhibitor cocktail and phosphatase inhibitor cocktail (Roche)]. 
Whole cell extracts (WCEs) were homogenized by sonication for 
10  s with a sonicator (Soniprep 150, MSE, London, UK) (45). 
Protein concentrations were determined by DC Protein Assay 
(Bio-Rad). In total, 100 μg WCEs were separated by 10 or 12% 
SDS-PAGE, then transferred to polyvinylidene fluoride (PVDF) 
membranes (EMD Millipore, Billerica, MA, USA), incubated 
with primary antibody overnight at 4°C, then horseradish perox-
idase-conjugated secondary antibody (Jackson ImmunoResearch 
Laboratory, West Grove, PA, USA) for 90 min and bands were 
detected by using the ECL reagent (Advasta, Menlo Park, CA, 
USA) with the BioSpectrum Image System (UVP, Upland, CA, 
USA). Protein or phosphor-protein levels were normalized to that 
of β-actin or corresponding total protein, respectively; and rep-
resented as fold changes compared with the control. The primary 
antibodies against interferon regulatory factor 3 (IRF3; #sc-9082), 
NF-κB p65 (#sc-372), and TSLP (#sc33791) were from Santa 
Cruz Biotechnology (Santa Cruz, CA, USA). Antibodies against 
RIG-I (#4520), IκBα (#4814), TBK-1 (#3504), phospho-TBK-1 
(Ser172, #5483), and phospho-NF-κB p65 (Ser468, #3039 and 
Ser536, #3033) were from Cell Signaling (Danvers, MA, USA). 
Anti-phospho-IRF3 (#ab76493) and anti-β-actin (#MA5-15739) 
antibodies were from Abcam (Cambridge, UK) and Thermo 
Fisher Scientific (Waltham, MA, USA), respectively.
nF-κB luciferase reporter assay
Cells cultured in 12-well plates were transfected with NF-κB-Luc 
reporter plasmids (46) by TurboFect. pRL-TK (Promega), encod-
ing Renilla luciferase under a herpes simplex virus thymidine 
kinase promoter, was an internal control. Twenty-four hours 
post-transfection, cells were stimulated with polyI:C. Cell lysates 
were collected for the dual-luciferase assay (Promega). Firefly 
luciferase activity was normalized relative to that of Renilla 
luciferase.
immunofluorescence assay
H292 cells were fixed in 4% paraformadehyde for 20  min and 
permeabilized with 0.5% Triton X-100 for 15 min, washed three 
times with PBS, then incubated with 10% skim milk in PBS for 
15  min to block non-specific antibody binding. To detect the 
cellular location of NF-κB p65 or IRF3, cells were incubated 
with antibodies against NF-κB p65 or IRF3 (1:500 in PBS) at 
4°C overnight, then with the secondary antibody biotinylated 
goat anti-rabbit IgG (1:500 in PBS, Thermo Fisher Scientific) at 
room temperature for 90 min, then Alexa Fluor 568 streptavidin 
(1:500 in PBS, Thermo Fisher Scientific) for another 90 min at 
room temperature. Nuclear counterstaining involved staining 
with 4′,6-diami-dino-2-phenylindole (DAPI) for 10 min at room 
temperature. Fluorescence signals were observed by fluorescence 
microscopy (ZEISS, Observer A1, Oberkochen, Germany). Anti-
HPeV VP0 antibody was used to detect HPeV1-infected H292 
cells (33).
nF-κB p65 and irF3 Knockdown
Short hairpin RNA (shRNA) specific to NF-κB p65 and IRF3 
was obtained from the National RNAi Core Facility, Institute of 
Molecular Biology/Genomic Research Center, Academia Sinica. 
HEK293T cells were transfected with shRNA lentivirus by using 
pMD.G, pCMV-ΔR8.91, PLKO.1 puro scramble control (shCtrl) 
or PLKO.1 puro shNF-κB p65 for 24  h, then culture medium 
was refreshed. Media containing lentivirus was harvested at 72 h 
post-transfection. H292 cells were infected with shNF-κB p65 or 
shCtrl lentivirus and infected cells were selected with puromycin 
(1 μg/ml) for 3 days.
statistical analysis
Significant differences between groups were analyzed by two-
tailed Student t-test with the software GraphPad Prism 5 (La 
Jolla, CA, USA). Data are presented as mean ± SD. P < 0.05 was 
considered statistically significant.
resUlTs
lPs-attenuated Polyi:c-induced TslP and 
il-33 expression and cell Damage
To investigate the hygiene hypothesis in airway epithelial cells 
in vitro, we used H292 cells because the gene expression profile 
of H292 airway epithelial cells is similar to that of primary nasal 
epithelial cells from healthy human controls on stimulation with 
house dust mite extracts (47). In studies of cell morphology, 
polyI:C stimulation induced damage in H292 cells at 12 h post-
transfection (Figure 1A), which is similar to previous findings 
(48). We noted that LPS treatment for 2  h dose-dependently 
protected cells against death induced by polyI:C, with high-dose 
(30 μg/ml) but not low-dose (3 ×  10−8 μg/ml) LPS conferring 
normal cell morphology (Figure  1A). PolyI:C-induced H292 
cell death was inhibited by LPS treatment for 2  h or 8  days 
(Figure 1B). The data suggest a cross-regulation between TLR4 
and TLR3 signaling pathway.
Gene expression of the allergic inflammation cytokines 
TSLP, IL33, and IL25 was measured in H292 cells. The TSLP 
and IL33 expression were significantly increased with polyI:C 
and IL4 treatment, by approximately three- to fivefold and 
FigUre 1 | Polyi:c-induced cell damage and allergic cytokine expression are attenuated by lipopolysaccharide (lPs) in airway epithelial cells. (a) 
H292 cells were treated with LPS (3 × 10−8, 0.3 and 30 μg/ml) for 2 h followed by polyI:C (2.5 μg) transfection for 12 h. Representative images from three 
independent experiments show that cell morphology under an inverted microscope. (B) H292 cells were treated with control medium (Ctrl) or 30 μg/ml LPS for 2 h 
or 8 days then stimulated with polyI:C (100 ng) for 3, 12, or 24 h. Cell viability was analyzed by WST-1 assay. Results are representative of three independent 
experiments. (c) H292 cells were treated with polyI:C (2.5 μg), LPS (30 μg/ml), or IL4 (20 ng/ml) for 3 h, and thymic stromal lymphopoietin (TSLP), interleukin 33 
(IL33) and IL25 mRNA expression was analyzed by RT-qPCR. (D) H292 cells were pretreated with LPS (0, 0.3, or 30 μg/ml) for 2 h, then stimulated with polyI:C for 
3 h. The expression of TSLP and IL33 were monitored by RT-qPCR and normalized to the internal control GAPDH; fold induction over controls is presented. Data of 
RT-qPCR values are mean ± SD from three independent experiments. Two- tailed student t-test, *P < 0.05, ***P < 0.001 compared to controls; #P < 0.05.
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twofold, respectively (Figure 1C) but not LPS. PolyI:C modestly 
increased IL25 expression, and IL4 has no effect (Figure 1C). 
PolyI:C and IL4-induced TSLP expression was also deter-
mined in A549 and WS-1 cells, respectively (Figures S2A–E in 
Supplementary Material). The polyI:C and IL4-induced TSLP 
and IL33 expression were also shown in NL20 cells, an immor-
talized, non-tumorigenic human bronchial epithelial cell line 
(Figures S3A–D in Supplementary Material). Low-dose LPS (0.3 
and 3 μg/ml) had no significant effect on the polyI:C-stimulated 
mRNA level of TSLP and IL33, but high-dose LPS (30 μg/ml) 
suppressed the increased TSLP and IL33 level (Figure 1D). The 
reduction of polyI:C-induced TSLP expression by LPS with a 
dose-dependent manner was also showed in the human primary 
nasal epithelial cells (Figures S4A,B in Supplementary Material). 
These data suggest that LPS concentration is critical for its 
inhibitory effect.
FigUre 2 | lPs downregulates polyi:c-triggered interferon regulatory factor 3 (irF3) and nF-κB activation. (a) H292 cells were stimulated with polyI:C 
(2.5 μg) for 3 and 12 h. Total cell extracts underwent SDS-PAGE and immunoblotting with specific antibodies. Data shown are representative of three different 
experiments. (B) Dual-luciferase assay of NF-κB luciferase reporters. H292 cells transfected with Luc reporter (0.6 μg) and pRL-TK (0.06 μg) were treated with 
polyI:C (2.5 μg) for 3–24 h. Data are mean ± SD from three independent tests. **P ≤ 0.01 vs. untreated group. (c) H292 cells were pretreated with doses of LPS as 
indicated for 2 h and then stimulated with polyI:C (2.5 μg) for 3 h. Cell extracts underwent SDS-PAGE and immunoblotting with specific antibodies. The signaling 
proteins expression level was analyzed by density meter and normalized to untreated control. Data shown are representative of three different experiments.  
(D,e) IRF3 and NF-κB p65 nuclear translocation was measured by immunofluorescence assay in H292 cells treated with LPS (30 μg/ml) for 2 h, then polyI:C 
stimulation for 3 h. Nuclear translocation rate is shown as mean ± SD from three observed fields. *P < 0.05 compared to controls. (F,g) H292 cells were transfected 
with control vector, wild-type IRF3, IRF3 5D (constitutive active IRF3), and IRF3 5A (dominate negative IRF3) for 48 h. The expression of TSLP and IL33 mRNA were 
measured by RT-qPCR and normalized to the internal control GAPDH. Values represent the average of three independent experiments ± SD.
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lPs Treatment inhibits Polyi:c-Triggered 
irF3 activation
TLR-mediated innate immune responses are elegantly regulated 
by several adaptive signaling proteins and transcription factors. 
In the TLR3 signaling axis, activation of the transcription fac-
tors IRF3 and NF-κB p65/50 by I kappa B kinase (IKK) and 
IKK-related kinases, such as TBK-1, IKKϵ, IKKα, and IKKβ, 
is required for transcription of downstream cytokines (6, 49). 
In H292 cells, this pathway could be activated by polyI:C, the 
IRF3 phosphorylation was detected at 3  h after stimulation 
(Figure  2A). And the conspicuous increases of phospho-
TBK1, -IRF3, and -NF-κB p65 (Ser456 and Ser536) were shown 
at 12 h (Figure 2A). The protein level of NF-κB p65 increasing 
and IκBα degradation was also noted (Figure 2A). The NF-κB 
activation by polyI:C was further validated by luciferase reporter 
assay (Figure  2B). Those data indicate the competent innate 
immunity in H292 cells.
To determine the mechanism why LPS-attenuated polyI:C-
induced TSLP and IL-33 expression, IRF3, and NF-κB were inves-
tigated, PolyI:C-induced IRF3 phosphorylation was inhibited by 
high-dose (30 μg/ml) but not low-dose LPS treatment in H292 
cells (Figure 2C). By contrast, the lowest dose of LPS (0.3 μg/ml) 
enhanced polyI:C-mediated IRF3 phosphorylation approximately 
2.4-fold as compared with polyI:C stimulation alone. PolyI:C 
stimulation induced an 11-fold decrease in IRF3 phosphorylation 
with 30 μg/ml LPS treatment as compared with 0.3 μg/ml LPS 
treatment (Figure 2C). Although the total NF-κB p65 level was 
not significantly changed, as compared with that observed with 
0.3 μg/ml LPS treatment, 3 and 30 μg/ml LPS treatment blocked 
the polyI:C-induced IκBα degradation by approximately twofold, 
which suggests that the polyI:C-mediated activation of the NF-κB 
pathway was downregulated with high-dose LPS (Figure  2C). 
The nuclear translocation of IRF3 and NF-κB confirmed that 
LPS significantly interfered with polyI:C-induced IRF3 and 
FigUre 3 | irF3 and nF-κB inhibitors suppress polyi:c-stimulated TslP and il33 expression. H292 cells were treated with NF-κB or IRF3 inhibitors 
dexamethasone (0.1, 1, and 10 μM) or Bay 11-7082 (1 and 5 μM) for 2 h, then challenged with polyI:C (2.5 μg) for 3 h. (a,c). The mRNA expression of TSLP and 
IL33 was measured by RT-qPCR. Data are mean ± SD from three independent experiments. *P < 0.05 compared to untreated controls with polyI:C stimulation. 
(B,D) Immunoblotting analysis with the indicated antibodies. Data shown are representative of three different experiments. The proteins expression level was 
measured by density meter; the value is normalized to untreated control.
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NF-κB activation (Figures 2D,E). The representative immuno-
fluorescence images are shown in Figure  S5 in Supplementary 
Material. IRF3 activity-associated TSLP and IL33 expression was 
further validated by ectopic expression of constitutive active IRF3 
(IRF3 5D) but not dominant negative IRF3 mutant (IRF3 5A) 
(Figures 2F,G).
Blocking irF3 or nF-κB activation inhibits 
TslP and il-33 induction
Based on the findings in Figures  1 and 2, blocking IRF3 and 
NF-κB activity by LPS treatment might be the key mechanism 
underlying the hygiene hypothesis. We further validated 
the role of NF-κB and IRF3 in TSLP and IL33 induction by a 
pharmatheutical approach. The NF-κB inhibitor dexametha-
sone (50) significantly downregulated TSLP and IL33 mRNA 
expression in H292 cells stimulated with polyI:C (Figure  3A), 
and immunoblotting data confirmed the inhibitory effect of 
dexamethasone in interfering with NF-κB activity by inhibiting 
IκBα degradation (Figure 3B). Although phospho-IRF3 level was 
enhanced in polyI:C-stimulated cells with dexamethasone treat-
ment (Figure 3B), this phenomenon did not alter the inhibitory 
activity of dexamethasone (Figure 3A). Bay 11-7082 is an IKK 
inhibitor that targets IKKα/β, TBK1, IRAK1/4, and TAK1 to 
modulate NF-κB and IRF3 activity (51). PolyI:C-stimulated TSLP 
and IL33 mRNA expression was inhibited in H292 cells treated 
with Bay 11-7082 (Figure 3C). Bay 11-7082 effectively inhibited 
polyI:C-induced IRF3 phosphorylation and IκBα degradation 
(Figure 3D).
The indispensable activity of IRF3 and NF-κB in TSLP and 
IL33 induction was further demonstrated by shRNA knockdown. 
IRF3 knockdown efficiency was confirmed by RT-qPCR, and 
FigUre 4 | TslP and il33 induction is inhibited in h292 cells with irF3 and nF-κB p65 knockdown with polyi:c stimulation. (a,c) H292 cells were 
infected with lentivirus carrying IRF3 and NFκB p65 shRNA. After puromycin selection, the mRNA and protein expression of IRF3 and NF-κB p65 was analyzed by 
RT-qPCR (left panel) and immunoblotting (right panel), respectively. Data shown are representative of three different experiments. (B,D) TSLP and IL33 mRNA 
expression was measured by RT-qPCR in H292 cells with IRF3 and NF-κB knockdown that were treated with polyI:C. Data are mean ± SD from three independent 
experiments. *P < 0.05, **P < 0.01.
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immunoblotting showed that polyI:C failed to induce IRF3 
protein expression and phosphorylation in H292 cells with 
IRF3 knockdown (Figure  4A). Importantly, polyI:C-induced 
TSLP and IL33 expression was inhibited with IRF3 knockdown 
(Figure 4B). The mRNA and protein levels of NF-κB p65 were 
not increased in knockdown cells with polyI:C stimulation 
(Figure 4C). In addition, polyI:C-induced TSLP and IL33 expres-
sion was inhibited with NF-κB p65 knockdown, by ~40 and 50%, 
respectively (Figure 4D). These data validated that the activity 
of IRF3 and NF-κB is associated with TSLP and IL33 induction 
by polyI:C.
lPs-attenuated hPeV1-Mediated TslP 
and il33 expression and signaling
To determine the TSLP and IL33 induction in H292 cells with 
viral infection, the cell was infected by HPeV1 for various times. 
The TSLP and IL33 levels were significantly induced at 48  hpi 
(Figure 5A). The expression of HPeV VP1 positive strain (+) and 
negative strain (−) genes showed HPeV1 replication in H292 cells 
(Figure 5B). HpeV1-induced TSLP expression was also shown 
in A549 cells (Figure S2F in Supplementary Material). To evalu-
ate whether LPS regulates HPeV1 infection-mediated allergic 
inflammation, H292 cells were treated with LPS before HPeV1 
infection (Figure  5C). Immunofluorescence assay showed no 
significant change of the HPeV1 infectivity in H292 cells with 
or without LPS treatment (Figure  5D); whereas, compare to 
untreated control cells, LPS significantly reduced TSLP and IL33 
level in H292 cells infected with HPeV1 (Figure 5E). Again, the 
data of HPeV1 VP1 gene expression indicated no effect of LPS 
in HPeV1 replication (Figure  5F). Immunoblotting analysis 
showed that LPS downregulated the phosphorylation of IRF3, 
TBK1, and NF-κB in HPeV1-infected H292 cells (Figure  5G). 
Taken together, these data suggest that LPS modulates HPeV1 
infection-triggered allergic cytokines expression.
long-term lPs Treatment inhibits TslP 
and il33 Production Pathways
The short-term treatment with high level LPS showed 
inhibitory effect of allergic cytokines response in epithelial cells 
(Figures 1–5), whereas the effect of long-term treatment of LPS 
remained to be explored. Thus, to establish long-term LPS-treated 
H292 cells, cells were incubated with LPS (30 μg/ml) and subcul-
tured every 2 days with LPS-containing medium. On day 8 of LPS 
treatment, cells were stimulated with polyI:C (Figure 6A). Similar 
to short-term LPS treatment, with long-term LPS treatment, with 
polyI:C, the increased mRNA expression of TSLP and IL33 was 
inhibited (Figure 6B). The polyI:C-induced TSLP protein level 
was inhibited by LPS treatment (Figure S6A in Supplementary 
Material). Furthermore, the protein levels of TLR3 downstream 
adaptor signaling proteins, phosphorylated TBK1, IRF3 were 
inhibited with high-dose (30 μg/ml), long-term LPS treatment 
and polyI:C stimulation for 3 and 12  h. The IκBα degradation 
FigUre 5 | lPs-attenuated hPeV1-mediated TslP and il33 expression and signaling. (a,B) TSLP and IL33, HPeV1 VP1 (+), and HPeV1 VP1 (−) 
expression were measured in H292 cells with mock or HPeV1 infection at various times. Data are mean ± SD from three independent experiments. (c) The 
schematic shows LPS treatment and HPeV1 infection in H292 cells. (D) Left panel: H292 cells, pretreated or untreated with LPS, were subjected to HPeV1 infection 
at multiplicity of infection (MOI) = 2.5. HPeV1 infectivity was analyzed by immunofluorescence assay with anti-HPeV0 antibody. HPeV1-infected cells show red 
fluorescence, and DAPI staining (blue color) show cell nuclei. The merged images show overlapping anti-HPeV VP0 and DAPI staining. Results are representative of 
three independent experiments. Right panel: HPeV1 infectivity was calculated from three observation fields. (e,g) TSLP and IL33, HPeV1 VP1 (+) and HPeV1 VP1 
(−) expression was measured in H292 cells with or without HPeV1 infection (Mock) and with (control medium) or without LPS treatment. (F) H292 cells were 
pretreated with or without LPS (30 μg/ml) then infected with or without HPeV1 (MOI = 2.5), then underwent immunoblotting with specific antibodies. Data are mean 
±SD from three independent experiments. *P < 0.05 compared to controls.
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was also downregulated by high-dose LPS treatment in H292 cells 
stimulated with polyI:C for 12 h (Figure 6C).
We also determined whether the basal mRNA level of sign-
aling proteins was changed with long-term LPS stimulation. 
Compared with untreated control cells, cells with long-term LPS 
treatment showed significantly downregulated basal mRNA level 
of NF-κB p65, MyD88, TRAF6, TLR3, NOD1, NEMO, and RIP1 
but not NOD2, IRAK1, or MAP3K7 (Figure 6D). Similar results 
were displayed in H292 cells with long-term LPS (30  μg/ml) 
treatment for 16 days that LPS decreased polyI:C-mediated TSLP 
and IL33 expression (Figure 7A). The polyI:C mediated-protein 
level of retinoic acid-inducible gene I (RIG-I, a dsRNA receptor), 
phosphorylated TBK1 and IRF3 were inhibited in H292 cells with 
LPS (30 μg/ml) treatment for 16  days (Figure  7B). Again, the 
basal mRNA level of singling protein genes were downregulated 
in those cells (Figure S6B in Supplementary Material). These data 
FigUre 6 | TslP and il33 induction is impaired in h292 cells with long-term lPs exposure. (a) The schematic shows long-term LPS treatment of H292 
cells. H292 cells were stimulated with LPS 30 μg/ml for 8 days, then with polyI:C (2.5 μg) for 3 h. (B) RT-qPCR analysis of mRNA levels of polyI:C-induced TSLP and 
IL-33 in H292 cells with long-term LPS (30 μg/ml) treatment. (c) H292 cells were treated with various doses of LPS for 8 days, then stimulated with polyI:C (2.5 μg) 
for 3 h. Immunoblotting analysis with the indicated antibodies. The ratio of signaling protein expression was normalized to medium control. Results are 
representative of three independent experiments. (D) RT-qPCR analysis of TLR signaling gene expression in H292 cells with long-term LPS treatment. Data are 
mean ± SD from three independent experiments. *P < 0.05 compared to control; #P < 0.05.
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suggest a fundamental transcription modulation in LPS-treated 
cells. Consequently, in these cells, allergic cytokine expression 
was decreased after polyI:C stimulation.
Our data indicated H292 cells with high level (30 μg/ml) LPS 
treatment for short term (2 h) and long term (8 and 16 days) were 
able to modulate polyI:C-induced TSLP and IL33 expression; but 
low-level (0.3  μg/ml) LPS treatment for 2  h showed no effect 
against allergic inflammation.
To evaluate the effect of low-level LPS and long-term treated 
H292 cells on TSLP and IL33 expression, LPS-trained H292 
cells were established via maintaining in low-level (0.3 μg/ml) 
LPS-containing growth medium for 60 days. The mRNA analysis 
FigUre 7 | Defective activation of rig-i-irF3 signaling axis in h292 cells with long-term lPs treatment. LPS-trained H292 cells were established by 
long-term treatment of high level LPS (30 μg/ml) and low-level LPS (0.3 μg/ml) for 16 days (a) and 60 days (c), respectively. RT-qPCR analysis of mRNA levels of 
polyI:C-induced TSLP and IL-33 are shown. The growth medium cultured cells were as the untreated control group. Data are mean ± SD from three independent 
experiments. **P < 0.01 compared to control. (B,D) The whole cell extracts from high level and low-level LPS-trained or untrained H292 cells were harvested at 3, 
6, 12, and 24 h after polyI:C stimulation. Immunoblotting analysis was performed with the indicated antibodies. Results are representative of three independent 
experiments.
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showed that polyI:C failed to induced TSLP and IL33 in the 
LPS-trained H292 cells (Figure 7C). In addition, similar to the 
H292 cells with long-term high-level LPS treatment, the polyI:C-
associated RIG-I, phosphorylated TBK1 and IRF3 expression was 
suppressed (Figure 7D).
hMBg1 acts in synergy with Polyi:c to 
induce TslP and il33 expression
To evaluate the role of HMGB1 in proallergic cytokines expres-
sion, the TSLP and IL33 RNA were measured in the H292 cell with 
HMGB1 stimulation for 3, 24, and 48 h. The HMGB1 alone was 
not able to induced TSLP and IL33, while polyI:C showed positive 
induction (Figures 8A,B). Although the IRF3 and NF-κB were 
activated at 24 and 48 h after HMGB1 stimulation (Figure 8C); 
however, those signals might not be enough for downstream 
TSLP and IL33 expression. We further evaluated that whether 
HMGB1 plays a similar role to LPS to attenuate the activity of 
polyI:C-mediated proallergic cytokine expression. Surprisingly, 
in the polyI:C-stimulated cells, the RNA level of TSLP and IL-33 
was increased by HMGB1 pretreatment for 3 h (Figures 8D,E). 
The immunoblotting also showed that HMGB1 enhanced the 
level of polyI:C-mediated IRF3 phosphorylation (Figure  8F). 
These results suggest that HMGB1 acts in synergy with polyI:C 
to promote TSLP and IL33 expression, which may be involved in 
allergic inflammation.
DiscUssiOn
In this study, we delineated the cellular and molecular roles of 
airway epithelial cells in hygiene hypothesis in vitro. Treatment of 
LPS could suppress the levels by subverting the polyI:C- and viral 
FigUre 8 | hMgB1 enhances polyi:c-stimulated TslP and il33 expression. (a,B) RT-qPCR analysis of TSLP and IL33 expression in H292 cells stimulated 
with polyI:C (2 μg) for 3 h or HMGB1 (1 μg/ml) for 3, 24, and 48 h. Data are mean ± SD from three independent experiments. ***P < 0.001 compared to control. 
(c)  The whole cell extracts from H292 cells were harvested at 3, 24, and 48 h after HMGB1 (1 μg/ml) stimulation. Immunoblotting analysis was performed with the 
indicated antibodies. Results are representative of three independent experiments. (D,e) H292 cells were pretreated with HMGB1 (1 μg/ml) for 3 h, then stimulated 
with polyI:C for 3 h. The expression of TSLP and IL33 were monitored by RT-qPCR. Data are mean ± SD from three independent experiments. ***P < 0.001 
compared to controls; #P < 0.05. (F) H292 cells were pretreated with HMGB1 for 3 h and then stimulated with or without polyI:C (1 μg) for 3 h. Cell extracts 
underwent SDS-PAGE and immunoblotting with specific antibodies. Data shown are representative of three different experiments.
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infection-mediated TBK1, IRF3, and NF-κB response. Therefore, 
the level of LPS exposure played a key role in inhibiting TSLP 
and IL33 expression in epithelial cells. Moreover, the DAMP 
inflammation factor HMGB1 increased the dsRNA-mediated 
proallergic cytokines expression. Blocking IRF3 and NF-κB by 
shRNA gene knockdown or inhibitors treatment suppressed 
TSLP and IL33 induction, so, in addition to TSLP and IL33, 
epithelium IRF3 and NF-κB activity could be targets for allergic 
inflammation therapy (52) (Figure 9).
Epithelial cells play key roles in bridging the innate and adap-
tive immune systems (15). The TLR signaling plays the crucial role 
in this system; however, TLR3 not only induce host inflammation 
response but also promote cell apoptosis (48). Physiologically, cell 
death is a host defense mechanism to restrict virus expanding; 
the exposed-viral antigen from death cells can trigger a series of 
immune response activation with cytokines releasing, which is 
usually associated with the viral pathogenic effects (53, 54). In 
our study, polyI:C-induced H292 cell death was inhibited by LPS 
treatment, which might refer that LPS-TLR4 interaction derives 
a negative regulation or a desensitization mechanism to provide 
protection against pathogen-mediated cell death (55).
Thymic stromal lymphopoietin is expressed mainly by epithe-
lial cells and epidermal keratinocytes; other types of cells, such 
as mast cells, smooth muscle cells, fibroblasts, dendritic cells, 
trophoblasts, and cancer or cancer-associated cells also express 
TSLP. TSLP expression in the epidermis, epithelium, and sub-
mucosa in skin, airway and ocular tissues plays critical role in 
the pathogenesis of allergic disease (56, 57). IL33 is abundantly 
expressed in epithelial cells from tissue exposed to the environ-
ment, and in fibroblastic reticular cells of lymphoid organ. IL33 
expression has been also observed in endothelial cells from blood 
vessels (58). The roles of TSLP and IL33 in allergy were evaluated 
in TSLP receptor (TSLPR)- and IL33 receptor-deficient (T1/
ST2) mice, respectively; TSLPR- and T1/ST2-knockout mice 
showed strong Th1 responses with high levels of IL2 and IFN-γ 
and impaired the Th2 response (59–61). The TSLP- and IL33-
mediated Th2 response was demonstrated in TSLP- and IL33 
knockout mice, respectively (60, 62). By contrast, lung-specific 
expression of a Tslp transgene induced Th2-mediated airway 
inflammation and hyperactivity (60). Epithelial cell-derived 
TSLP mediates chemotactic activity in dendritic cells and airway 
smooth muscle cells (63, 64), which may be associated with the 
FigUre 9 | lPs inhibits polyi:c- and virus-induced proallergic cytokines expression via targeting TBK1, irF3, and nF-κB response. A schematic model 
shows the possible mechanism of the LPS modulating TSLP and IL33 in airway epithelial cells. The polyI:C or HPeV1 activated TLR signaling is inhibited in the cells 
with short- and long-term LPS exposure, or inhibitors (Dexamethasome and Bay11-7082) treatment, which lead to a defective expression of TSLP and IL33.
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development of allergy. During allergic inflammation initia-
tion, polyI:C- or dsRNA-induced TSLP and IL33 derived from 
epithelium are critical to activate dendritic cells to produce IL4, 
IL5, and IL13 and to promote Th2 responses. In turn, the posi-
tive feedback provided by IL4, IL5, and IL13 upregulates TSLP 
and IL-33 production in various cell types, which may aggravate 
allergic inflammation (Figure S7 in Supplementary Material) (10, 
16, 56, 65–67). Thus, blocking TSLP and IL33 activity by antibody 
or signaling inhibitors may be considered for atopic disease 
therapy (68, 69). Alternatively, inhibition of TSLP and IL33 levels 
in epithelial cells may effectively attenuate allergic responses.
In this study, we demonstrated that TSLP and IL33 were 
induced by polyI:C and HPeV1 stimulation in H292 cells, which 
supported result from the previous study of primary bronchial 
epithelial cells (70). Nevertheless, our model also serves as a 
cell line-based platform for anti-allergy drug screening. We 
found that dexamethasone and Bay 11-7082 inhibited TSLP and 
IL33 expression by downregulating IRF3 and NF-κB activities. 
Coincidentally, the essential roles of the IRF3 and NF-κB path-
ways in TSLP and IL-33 induction were demonstrated in other 
research models [(16, 71–75), Schuijs et al. (76) #5788]. Moreover, 
we found that LPS-modulated IRF3 and NF-κB activation in the 
polyI:C or HPeV1/TLR3 axis could be the causal mechanism of 
hygiene hypothesis. Our findings are supported by a current study 
that farm dust and LPS attenuated house dust mite-mediated 
allergic response in respiratory epithelial cells (76).
The dose of LPS is one of the critical factors in the establish-
ment of airway allergy. However, the used- dose of LPS in vitro 
experiments was varied. In primary cells, such as macrophages, 
dendrite cells, or embryonic fibroblast, 100 ng/ml–1 μg/ml of LPS 
is sufficient to activate innate immunity (77–80). However, in the 
macrophage cell line (JA774A.1) or lung carcinoma epithelial 
cells (A549 and BEAS-2B cells), 10–100 μg/ml of LPS was used 
to change cellular behaviors (40, 55). In our model, TSLP and 
IL33 production were downregulated in H292 cells with 30 μg/
ml of LPS, short-term treatment or 0.3 μg/ml of LPS, long-term 
treatment. Moreover, 4–12  μg/ml of LPS also attenuate TSLP 
expression in human primary nasal epithelial cells. We thought 
that our data are not conflicting in certain with the previous 
reports; moreover, it also suggests that the stimulation dose of 
LPS and time course were critical factors in the inhibition of 
allergic cytokine induction.
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We had tried to test our hypothesis in an experimental 
mouse model of allergic rhinitis; however, the animal model was 
extremely hard to conduct and there were several points, which 
are difficult to overcome in our system. First, mice always sneezed 
and rubbed their noses until the fluid flowed out after reagent 
solutions, such as LPS were dropped into their nasal cavity, so 
the scheduled incubation period of 1–3 h became unreliable and 
the stimulating dosage unreliable too. Second, when the reagent 
solutions stimulated the nasal cavity, we cannot differentiate 
whether the effects came from stimulation of the dendritic cells or 
epithelial cells. We thought that establishment of a proper animal 
model would be required for further translation approach.
Even though, the effect of LPS dose was investigated in mice 
reported by others, that low-dose LPS induced Th2 responses, 
but high-dose LPS with antigen treatment resulted in Th1 
responses (29). Therefore, the level of LPS exposure can deter-
mine the skew of Th1/Th2 responses and provide a potential 
mechanistic explanation for epidemiological findings on LPS 
exposure and asthma prevalence involving the activation of 
antigen-containing dendritic cells (29). However, in this mouse 
model, only endpoint analysis was accessed; it would be of inter-
est to investigate the immunoregulatory effect in mice receiving 
low-level LPS for an extended/long-term period. In addition, the 
physical effective dose of LPS may be varied among LPS from 
various bacteria (40); so, the different allergic regulation activity 
may be observed in mice challenged with various types and dose 
of bacterial LPS.
We show that short- and long-term LPS exposure had similar 
inhibitory effects in polyI:C/TLR3-axis-mediated TSLP and IL33 
expression, with certain signaling-protein gene transcripts down-
regulated in H292 cells after treatment with high-dose LPS for 8 
and 16 days. We also found that low-dose LPS-suppressed expres-
sion of TLR signaling genes was substantial in H292 cells treated 
with LPS for 2 months. Therefore, LPS silenced the TLR-mediated 
innate immunity, which may occur at the gene transcription level 
and be controlled by chromatin modification activity (81, 82). 
Thus, determining whether the epigenetic regulation of the host 
response to LPS is involved in the hygiene hypothesis would be 
of interest.
A recent study proposed a hypothesis about early life airway 
exposure to microbial pathogens and the development of 
asthma, which suggests that specific microbial colonization 
and co-infection of bacteria and viruses such as Streptococcus 
and Corynebacterium, respiratory syncytial virus and human 
rhinoviruses in infants was a strong predictor of persistent 
asthma developing by 5  years of age. Additionally, antibiotic 
treatment reduced this risk by disrupting microbial colonization 
(83, 84). The hypothesis that infections trigger asthma suggests 
an additional opinion on the hygiene hypothesis and refers to the 
sophisticated regulation of specific microbes and a host defense 
system that affect the occurrence of atopy. Therefore, our data 
raise important issues as to whether different LPS resources from 
various microbes have different inhibitory outcomes.
The LPS from Escherichia coli 0111:B4 was mainly used in 
this study, but LPS derived from other bacteria, such as Klebsiella 
pneumoniae or Salmonella enteric, were also tested. Although, the 
inhibitory effect of all these LPS on polyI:C were observed, but the 
implication of the pathogenic bacteria infection in allergy remains 
to be explored. Moreover, determining whether the inhibitory 
effect of LPS could be demonstrated with other bacterial compo-
nents, such as peptidoglycan, teichoic acid, or phosphorylcholine 
in airway epithelial cells would be of interest (85).
High-mobility group protein B1 act as endogenous danger 
signals to promote and exacerbate the inflammatory response 
(37, 38, 86, 87). Given the relevance of HMGB1 as a ligand for 
TLRs (88, 89), we tested the activity of HMGB1 in our in vitro 
model. We found that HMGB1 itself was not able to induce TSLP 
and IL33 expression. However, in the polyI:C-stimulated cells, 
the level of TSLP and IL33 expression and IRF3 phosphorylation 
was enhanced by HMGB1; which is contrary to LPS treatment on 
the regulation of allergic inflammation. We thought that certain 
additional activation signaling derived from HMGB1 receptor 
other than TLR4, such as RAGE, might contribute to dsRNA-
mediated allergic inflammation (90). Thus, it would be important 
to future evaluate whether HMGB1 would be a therapeutic target 
for allergy (91).
To the best of our knowledge, our study is the first to delineate 
a cellular and molecular mechanism of the hygiene hypothesis 
via TLR signaling in epithelial cells. In addition, we also revealed 
HPeV1 elicits allergic inflammation. Varying the concentrations 
or treatment time course of TLR4 agonist could regulate TLR3-
associated allergic inflammation for a new strategy to combat 
allergic diseases.
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